TY - JOUR AU - Sumarsono, Hadi AU - Laksmitawati, Dian Ratih AU - Irwanto, Ronald PY - 2020/10/28 TI - Effectiveness of Meropenem-Levofloxacin with Meropenem-Amikasin Towards LOS & Leukocytes to RASPRO III Stratification Community Pneumonia Patients JF - JURNAL ILMU KEFARMASIAN INDONESIA; Vol 18 No 2 (2020): JIFIDO - 10.35814/jifi.v18i2.880 KW - N2 - Administration of antibiotics in the private hospital "X" adopted a concept called Ronald Irwanto Antimicrobial Steweardship Program (RASPRO). The suggestion of an empirical antibiotic combination in type III stratifi cation community pneumonia patients was meropenem-levofl oxacin or meropenem-amikasin. The aim of the study was to determine the eff ect of empirical antibiotic combination meropenem-levofl oxacin with meropenem-amikacin to RASPRO type III stratifi cation community pneumonia patients towards the LOS and decreased leukocytes. The test sample calculated using diff erence between two population proportions formula and analysed using Chi-square method. Diabetes mellitus, immobilisation and geriatrics as confounding variables were controlled by logistic regretion multivariate analysis. The results showed that meropenem-levofl oxacin had a tendency 1.81 times to experience LOS < 5 days and 0.92 times to experience decreased leukocytes ≥ 10% compared to meropenem-amikacin, but both were not signifi cant (p 0.161 and p 0.835). The result control of confounding variables were found that geriatrics as a meaningful confounding variable eff ect of LOS and no confounding variables were considered to aff ect the decreased leukocytes. In conclusion, there is no eff ect of empirical antibiotic combination meropenem-levofl oxacin with meropenem-amikacin towards the LOS and decreased leukocytes to RASPRO type III stratifi cation community pneumonia patients using statistics after controlling the confounding variables. UR - http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/880